TuHURA Biosciences (HURA) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing three novel immuno-oncology technologies to address resistance in cancer immunotherapies.

• Lead asset IFX-2.0 targets primary resistance in Merkel Cell Carcinoma (MCC) and is in Phase 3 with accelerated approval pathway.

• TBS-2025, a VISTA-inhibiting monoclonal antibody, is entering Phase 1b/2 for AML and MDS, targeting negative immune regulators.

• Developing first-in-class bi-specific, bi-functional ADCs targeting MDSCs and Tregs to overcome acquired resistance.

• $50 million credit facility and royalty transaction provide non-dilutive capital, supporting operations through Q1 2028.

Clinical programs and milestones

• IFX-2.0 Phase 3 trial in 1st line MCC expects topline data in 2H 2027; SPA agreement with FDA and no confirmatory trial anticipated.

• Phase 1b/2 study of TBS-2025 in AML to initiate in 2H 2026, led by a former JNJ executive.

• ADC proof-of-concept data expected in 2H 2026, offering potential partnering opportunities.

• Orphan Drug Designation milestones targeted for both MCC and AML programs.

• Multiple scientific presentations planned across portfolio assets.

Merkel Cell Carcinoma (MCC) market and clinical need

• MCC is a rare, aggressive skin cancer with ~3,800 new cases annually; 75% present with advanced disease.

• 50% of patients do not respond to first-line Keytruda; no approved therapies exist for those who fail.

• Improving Keytruda response rates in first-line MCC represents a significant commercial opportunity.

• Addressable market estimated at ~3,000 patients.